Biogen Inc. (BIIB)

Total revenue has been declining 5-8% annually as MS biosimilar erosion (particularly generic Tecfidera) overwhelms new product contributions. Biogen trails every large-cap biotech peer in organic growth — Regeneron, Vertex, and AbbVie are all growing while Biogen shrinks. The company's FY2026 revenue is projected below $9B, down from $13B+ at peak.

Biogen is losing MS market share rapidly to newer oral therapies (Mavenclad, Kesimpta) and anti-CD20 antibodies (Ocrevus) while facing biosimilar pressure on older products. In Alzheimer's, Leqembi has captured meaningful but disappointing share, with Eli Lilly's donanemab providing direct competition. The rare disease portfolio is too small to move the needle on overall share metrics.

Pricing power is evaporating in MS as biosimilars compress the category and payers increasingly mandate step therapy. Leqembi pricing at ~$26,500/year is under scrutiny given modest clinical benefit. Medicare coverage with evidence development adds reimbursement friction. Biogen has been forced into net price declines across the MS portfolio.

The pipeline is thin for a company of Biogen's size. Leqembi subcutaneous formulation could improve convenience, but the underlying efficacy debate remains. Beyond Alzheimer's, the pipeline consists of mid-stage neuropsychiatry and neurology assets with binary clinical trial risk. The Reata acquisition was an admission that internal R&D wasn't generating sufficient new products.

Physician switching costs in neurology are moderate — neurologists are conservative about changing stable MS patients off working therapies, creating some Tysabri and Avonex stickiness. However, new patient starts increasingly go to competitors. In Alzheimer's, switching costs are minimal as the category is nascent and treatment protocols are still being established.

No network effects in biotech. Biogen's physician relationships and KOL networks are valuable but don't create self-reinforcing dynamics. The Alzheimer's launch requires building infusion center infrastructure and PET imaging networks, which creates some ecosystem-like dynamics but benefits all amyloid-targeting drugs, not just Leqembi.

Biogen's patent protection on MS therapies has largely expired or is expiring — Tecfidera lost exclusivity, and Tysabri faces biosimilar competition. Leqembi has composition of matter patents extending to the mid-2030s, providing a decade of exclusivity if the drug succeeds commercially. Skyclarys orphan drug exclusivity provides 7 years of market protection.

Biogen maintains significant biologic manufacturing capabilities that represent a barrier to entry, but excess capacity from declining MS production is a drag on margins. Free cash flow generation remains solid (~$2-3B annually) but is declining. The biosimilar joint venture with Samsung provides additional manufacturing revenue but is a low-growth, low-margin business.

EPS estimates have been persistently revised downward as Leqembi launch tracking disappoints and MS erosion accelerates. FY2026 consensus EPS has dropped 15%+ over the past 12 months. The only positive revision catalyst is a Leqembi uptake inflection that analysts have been waiting for but hasn't materialized.

The Alzheimer's narrative has shifted from transformative to disappointing — Leqembi uptake data, amyloid-related imaging abnormality safety concerns, and the debate over clinical meaningfulness of 27% slowing in cognitive decline dominate coverage. The Aduhelm debacle still colors Biogen's credibility with investors. Positive pipeline readouts could shift sentiment quickly, but the market demands proof.

CEO Christopher Viehbacher has made decisive moves (Reata acquisition, cost restructuring, Aduhelm discontinuation) but the strategic direction remains unclear — is Biogen an Alzheimer's company, a rare disease company, or a neuroscience platform? The $7.3B Reata price tag looks aggressive for a single-product acquisition. Share buybacks at declining earnings multiples have consumed capital that could have funded additional pipeline.